Leflunomide Aurobindo

Leflunomide, the active ingredient in Leflunomide Aurobindo, is an immunomodulatory agent presented as a tablet for oral use. It is used to treat rheumatoid arthritis and psoriatic arthritis in adult patients. GNH USA supplies Leflunomide Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leflunomide is a disease‑modifying antirheumatic drug that acts on autoimmune joint disorders.

Rheumatoid arthritis: reduces joint inflammation, pain and slows structural damage. Psoriatic arthritis: improves skin lesions and joint symptoms, helping maintain function.

Leflunomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Diarrhoea: loose stools occurring during early therapy. - Nausea: feeling of sickness or upset stomach. - Alopecia: thinning or loss of hair. - Rash: skin redness or itching. - Elevated liver enzymes: mild increase in ALT/AST. - Hypertension: rise in blood pressure.

Serious or Rare Side Effects: - Severe liver injury: jaundice, hepatic failure. - Stevens‑Johnson syndrome: severe skin blistering. - Bone marrow suppression: low blood cell counts. - Interstitial lung disease: breathing difficulty, cough. - Severe infections: opportunistic bacterial or viral infections. - Teratogenicity: birth defects if exposure occurs during pregnancy.

Before initiating Leflunomide, clinicians should evaluate several safety parameters.

Pregnancy contraindication: avoid use in women who are pregnant or may become pregnant. Liver function monitoring: check ALT/AST before start and periodically thereafter. Blood count monitoring: assess complete blood count regularly. Hypertension surveillance: monitor blood pressure throughout treatment. Infection risk: screen for active infections and avoid live vaccines. Store below 25°C: keep in the original pack, protect from moisture.

Leflunomide can alter the activity of several co‑administered medicines.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, risk of bleeding. - Teriflunomide: additive toxicity, especially hepatic. - Live vaccines: risk of uncontrolled infection. - Immunosuppressants (e.g., cyclosporine): heightened immunosuppression. - Cholesterol‑binding resins (e.g., cholestyramine): reduced Leflunomide absorption.

Moderate Interactions (Monitor Closely): - Statins: possible increase in muscle toxicity. - Antihypertensives: additive blood‑pressure lowering. - Oral contraceptives: reduced efficacy, consider alternative methods. - NSAIDs: may increase liver enzyme elevations. - Methotrexate: combined bone‑marrow suppression risk.